Apellis Announces Pegcetacoplan Showed Continuous and Clinically Meaningful Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)
March 16, 2022
Both monthly and every-other-month pegcetacoplan continued to reduce GA lesion growth compared to pooled sham at 18 months with all p-values (nominal) below 0.05 Treatment